GSK rolls out new DTC ads for Lovaza

Share this article:
GSK rolls out new DTC ads for Lovaza
GSK rolls out new DTC ads for Lovaza

GlaxoSmithKline launched new TV spots last week for Lovaza, a prescription omega-3 fish oil capsule indicated for the lowering of very high triglyceride levels.

TV spots, as well as the consumer print and online ads that debuted in January, emphasize the drug's natural ingredient: "Lovaza — the prescription that starts in the sea." On television, a white-coated physician handles beakers in a lab surrounded by a gigantic wall-sized aquarium.

Bernadette King, a GSK spokesperson, said the campaign targets "people at higher risk," such as Type 2 diabetics, people with high blood pressure, high cholesterol, and the overweight. "There's a big potential to educate consumers on high triglycerides," she said.

King hastened to add that Lovaza is not indicated for the prevention of cardiovascular events. The campaign is geared toward reducing high triglyceride levels and building awareness around the disease, she said. "We hope it will promote patient-doctor dialogues, which should be the focus of any DTC campaign," said King

McCann HumanCare created the DTC work for Lovaza, and imc2 worked on digital and online elements, said King.

Online content at Lovaza.com includes patient testimonials and a "Put Lovaza to the Test" game for visitors. A coupon on the website offers $20 off 12 refills of the drug, which costs around $160 for a month supply, according to Consumer Reports.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.